targeting
Navigation Links
targeting at medicine technology
Prothrombin Time Comes in Small (CLIA-Waived) Packages
...le-application area and flashing light make sample targeting easy. The meter recognizes errors and controls are identified automatically. Automatic internal controls monitor the meter and test strip for accurate function. International Technidyne Corp., Edison, N.J., manufactures the ProTime Microcoagulation S......mber of different enzymes in its portfoliothat are targeting significant areas of unmet need. Safe Harbor Statement In addition to historical information, the statements set forthabove include forward-looking statements (including, withoutlimitation, statements concerning the applicability of rHuPH20 tolarge...... platform, including its recentvalidation for dual targeting purposes, has enormous potential forapplication to human diseases that are currently inadequatelytreated." The data will be presented for the first time on August 9th 2007at IBC's Drug Discovery Technology Conference in Boston, MA,USA. Pieris is no...Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings
...ab. "This new research confirms that Neuradiab is targeting a keymarker in the progression of GBM that is also...cientific research which supports therationale for targeting tenascin-C with a local mechanism of actionin the GBM setting. This ongoing research complements the......e expression vector -nicknamed VISA. It includes a targeting agent, also called apromoter, two components that ... what became C-VISA-BikDD. They used a gene-based targeting promoter called CCKAR known tobe active in pancreatic cancer but not in healthy pancreatictissue. Th......or thetreatment of metabolic and liver diseases by targeting the liverand liver pathways, announced today that ...s clinical stage and preclinicalproduct candidates targeting major diseases with significant unmetmedical needs. Targeted diseases include major metabolic diseas...Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...SE(R), is an RNase that overcomes thechallenges of targeting RNA for therapeutic purposes while enablingthe development of a new class of targeted therapies for cancer andother life-threatening diseases. In addition to an ongoing PhaseIIIb study in malignant mesothelioma, Alfacell is conducting aPhase I/II tri......only seenwith other antibodies and small molecules targeting the tyrosinekinase pathway indicates that nimotuzumab has the prospect of being"best-in-class" without compromised efficacy," said David Allan,Chairman and CEO of YM BioSciences. About nimotuzumab Nimotuzumab is a humanized monoclonal antibody that...... Research suggests thata monoclonal antibody (mAb) targeting ANGPTL4 may have therapeuticapplication in the treatment of cardiovascular disease. The resultsappeared in an article, entitled "Lipid-lowering effects ofanti-angiopoietin-like 4 antibody recapitulate the lipid phenotypefound in angiopoietin-like 4 k...Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
...ute;first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Phase I study in healthy volunteers is designed to assesssafety, tolerability and pharmacokinetics of ALX-0081. It will alsoanalyse phar...Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
...PA replacement therapy. Theglobal market for drugs targeting Parkinson's disease was $1.7billion in 2003 and is forecast to grow substantially over the nextdecade with an increased prevalence of the disease as a consequenceof the ageing population. COMT inhibitors currently have more thana 10% share of the Par...Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
...and commercialize novel small moleculetherapeutics targeting human mitotic kinesins for applications inthe treatment of cancer and other diseases. All threeclinical trials were sponsored by the National Cancer Institute(NCI). A Phase II clinical trial designed to evaluate the safety andefficacy of ispinesib ......rous autoimmune diseases with an initialindication targeting refractory relapsing-remitting MultipleSclerosis. Revimmune is based on pulsed, ultra-high dosing of awell-known chemotherapeutic agent under a risk management program.Additionally, through an investment strategy, the Company hasacquired the majority......aparsin induces cell cyclearrest and cell death by targeting several cellular pathwaysessential for cell survival. Exposure to darinaparsin has a directas well as indirect effect on mitochondrial functions, resulting indepletion of energy supply to the cell and induction of apoptosis(programmed cell death). In...... the QUADRAMETpackage insert. QUADRAMET pairs the targeting ability of a small molecule,bone-seeking phosphonate (EDTMP) with the therapeutic potential ofradiation (samarium Sm-153). Skeletal invasion by prostate, breast,multiple myeloma, and other cancers often creates an imbalancebetween the normal process ......rous autoimmune diseases with an initialindication targeting refractory relapsing-remitting MultipleSclerosis. Revimmune is based on pulsed, ultra-high dosing of awell-known chemotherapeutic agent under a risk management program.Additionally, through an investment strategy, the Company hasacquired the majority......ONASE, is an RNase that overcomes thechallenges of targeting RNA for therapeutic purposes while enablingthe development of a new class of targeted therapies for cancer andother life-threatening diseases. In addition to an ongoing PhaseIIIb study in malignant mesothelioma, Alfacell is conducting aPhase I/II tri...MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
...pical delivery system in late-stage clinicaltrials targeting infectious and inflammatory skin diseases andcondi...mpany’s major efforts are focused onprojects targeting Raynaud’s phenomenon, nail psoriasis andactinic keratosis. In addition to historical facts or...Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
...nticipated. deCODE is thus very encouraged that in targeting EP3,the company is advancing a potentially major n...1 - Heart attack In its drug development programs targeting the leukotrienepathway for the prevention of heart attack, deCODE is advancing thereformulation of i...... Galvus works through a novel mechanism of action, targeting adysfunction in the pancreatic islets that causes high blood sugarlevels in people with type 2 diabetes. In clinical studies, Galvushas demonstrated significant reductions in blood sugar sustained attwo years[8]. At a special ceremony during the con......r is currently in IND-enablingstudies with EX-1314 targeting a variety of therapeuticindications. Further, in March 2006, Elixir in-licensed North and SouthAmerican rights to Glufast(R) (mitiglinide calcium hydrate), aninsulin secretagogue, which lowers post-meal glucose levels byimproving the body's own abil......r is currently inIND-enabling studies with EX-1314 targeting a variety oftherapeutic indications. Elixir also has developed expertise and a broad IP portfolio ofmore than twenty patents and patent applications related to theSirtuin class of proteins, including small molecular weight SIRT1activators and inhibi......-7:30 p.m. About ACTOS ACTOS works by directly targeting insulin resistance, acondition in which the body does not efficiently use the insulin itproduces to control blood glucose levels. ACTOS is taken once dailyas an adjunct to diet and exercise, and is approved for use fortype 2 diabetes as monotherapy t......in(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr And...e therapeutic application of itstechnologies, dual targeting is viewed as a major step forward.Combining the benefits of bivalent, avid binding of disease target...Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
...l-dextran). Lymphoseek is a proprietaryradioactive targeting agent being developed for use with handheldgamma detection devices, such as Neoprobe's neo2000(R) system, in asurgical procedure known as Sentinel Lymph Node Biopsy (SLNB). Theprimary endpoint of this multicenter, single-arm, open-label,within-patien...Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
... important tools for the discoveryof new therapies targeting diseases of the central nervoussystem. <p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 12pt; mso-layout-grid-align: none">Millipore’s Bioscience Division provides innovative tools,services and biological reagents that drive advancements ......ic peptide (PCK3145), a tumor andtumor-vasculature targeting (TVT) technology platform, as well asother anti-virals and immunomodulators. Exclusive worldwide rightsto PPL-100 and its related compounds have been granted to Merck& Co., Inc. in return for a $US 17 million upfront payment,potential milestones ......ning and leadoptimization technology. PRX-00023 is targeting a significant unmetmedical need and commercial opp...maging drug candidatescurrently in clinical trials targeting conditions such asdepression, Alzheimer's disease, cardiovascular disease andobesity. These drug can...Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
...s of survivin function and adrug discovery program targeting the MYC oncoprotein, one of themost important and previously intractable cancer targets. Thecompany has value generating partnerships with Merck, MedImmune,Medarex, and Novartis. Avalon Pharmaceuticals was established in1999 and is headquartered in G......), as well as a proprietary drug discoveryplatform targeting GPCRs (G-Protein Coupled Receptors). For further information, please contact: Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +441273 675100 <a target="_blank" href="mailto:allo@ala.com%3Eallo@ala.com">allo@ala.com>allo@ala......ing a fundamentally different treatmentapproach by targeting B cells, one of the key players in thepathogenesis of RA. Actemra is Roche's second novel medicine and isa humanised monoclonal antibody to the interleukin-6 (IL-6)receptor, inhibiting the activity of IL-6 , a protein that plays amajor role in the RA...... liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that ...ntificexpertise, including unique capabilities for targeting the liverand liver pathways, the Company has established a pipeline thatincludes preclinical and cli...Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
...ximab), thefirst approved IgG1 monoclonal antibody targeting the epidermalgrowth factor receptor (EGFR) developed and commercialized byImClone Systems Incorporated, was the focus of nine oral and 46poster presentations at the recently concluded 43rd Annual Meetingof the American Society of Clinical Oncology (A...Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
...ut hPAM4 hPAM4 is a humanized monoclonal antibody targeting an epitope inthe MUC1 antigen expressed in most pancreatic cancer, but notpancreatitis, normal pancreas or most other normal tissues.Preclinical studies with PAM4 labeled with the radioisotope,Yttrium-90, demonstrated favorable tumor responses, which......r is currently in IND-enablingstudies with EX-1314 targeting a variety of therapeuticindications. Further, in March 2006, Elixir in-licensed North and SouthAmerican rights to Glufast(R) (mitiglinide calcium hydrate), aninsulin secretagogue, which lowers post-meal glucose levels byimproving the body's own abil......in-class and highly active IgG1 monoclonalantibody targeting the epidermal growth factor receptor (EGFR). Asa monoclonal antibody, the mode of action of Erbitux is distinctfrom standard non-selective chemotherapy treatments in that itspecifically targets and binds to the EGFR. This binding inhibitsthe activati...Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
...and commercialize novel small molecule cancerdrugs targeting Hsp90 and the Hedgehog cell-signaling pathway. The...ral versions of IPI-504, and a series of molecules targeting theHedgehog cell signaling pathway. About Infinity Pharmaceuticals, Inc. Infinity is an innovative...Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
...ssionand, unlike DNA mutations, may be reversed by targeting the enzymesinvolved. The silencing of key cell cyc... and Gemzar(r). MGCD265 is an oralkinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptortyrosine kinases. In addition, MethylGene has several preclin......he BEXXAR Therapeutic Regimen(4) BEXXAR pairs the targeting ability of a monoclonal antibody(Tositumomab) and the therapeutic potential of radiation(Iodine-131). Combined, these agents form a radiolabeled monoclonalantibody regimen that is able to bind to the target antigen CD20found on B cells, including nor...Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
...om 1995 to 1998 with two differentpeptide vaccines targeting the RAS mutation found in most instancesof pancreatic cancer indicates that a long lasting immune responseis possible following immunization with a peptide vaccine. Fivepatients that showed an immune response to the vaccine were stillalive in 2006, i......lengitide is a highly selective integrin inhibitor targeting thetumor and its vasculature. Fifty-two patients with newly diagnosed glioblastoma weretreated with cilengitide, combined with a standard regimen ofradiotherapy and temozolomide following tumor resection or biopsy.The study reached the predefined pr......in-class and highly active IgG1 monoclonalantibody targeting the epidermal growth factor receptor (EGFR),outside the US and Canada from ImClone Systems Incorporated of NewYork in 1998. In Japan, Merck KGaA has co-exclusive marketingrights with ImClone Systems. Erbitux is being investigatedprincipally in colore...Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
...noglycoside portion of doxorubicin. Peptide-based targeting of tumors is an attractive approach fortumor selec...of innovative anti-cancer drugswith enhanced tumor targeting or improved biodistribution. Diatosis expanding its portfolio of drug candidates with new compoundst...Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
...of the 12 assessable patients, indicatingeffective targeting of leukemic cells by epratuzumab. At the timeof reporting, 9/12 patients (75%) achieved a complete remission, ofwhom 7 showed no residual disease by flow cytometry; 1 patient hada partial response, 1 stable disease, and 1 with diseaseprogression. ...New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting
... the QUADRAMETpackage insert. QUADRAMET pairs the targeting ability of a small molecule,bone-seeking phosphonate (EDTMP) with the therapeutic potential ofradiation (samarium Sm-153). Skeletal invasion by prostate, breast,multiple myeloma, and other cancers often creates an imbalancebetween the normal process ...... prostate tumors specificallyand non-invasively by targeting PSMA expression on prostate cancercells. A PSMA-targeted molecular imaging pharmaceutical such asMIP-1072 may lead to improvements in the staging of prostate cancerpatients and may represent a unique opportunity to risk stratifypatients and monitor r......ut not in healthy tissue, and that themechanism of targeting solid tumors is independent of tumor type.To date the drug has had no effect on renal, liver or immunefunction and no unexpected serious adverse events have beenreported. CYT-6091 induces a predictable and controllable febrileresponse, and has yet to...Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
...and commercialize novel small molecule cancerdrugs targeting Hsp90 and the Hedgehog cell-signaling pathway. The...ral versions of IPI-504, and a series of molecules targeting theHedgehog cell signaling pathway. About Infinity Pharmaceuticals, Inc. Infinity is an innovative...DP-b99 Phase IIb Trial Results to be Presented at the European Stroke Conference
...as generated a rich product pipeline from its drug targeting anddiscovery technologies, Regulated Activation of Prodrugs (D-RAPTM)and Membrane Active Chelators (MAC). The company expects to discussthe further development of DP-b99 with regulatory authorities inthe coming months. D-Pharm's pipeline includes DP...Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
...tosar(R)) to tumours with reducedside-effects. The targeting of drug to the tumour, coupled with theability of HyCAMP(TM) to deliver more doses due to lower toxicity,has been successfully translated into man with a greatertherapeutic benefit to patients in this Phase II trial comparedwith Camptosar(R)." Dr Sm...Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
...y has four product candidates in development:three targeting influenza and pandemic flu and one to prevent E.coli-related travelers' diarrhea. For more information on Iomai,please visit <a target="_blank" href="http://www.iomai.com/">http://www.iomai.com . CONTACT: Russell P. Wilson, Senior Vice Presi...MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
...clinicalstudies with its monoclonal antibody (MAb) targeting IL-9 andpreclinical data demonstrating a central r... identification of small molecule inhibitors targeting interferon-alpha signaling pathways," J. Immunol., Apr 2007; 178: 131.17. -- "Fc dependent ......veral clinical and preclinical-stageprograms, each targeting distinct chemokine and chemoattractantreceptors with different small molecule compounds. ChemoCentryx'slead compound, Traficet-EN(R), a specific CCR9 antagonist, iscurrently in a multi-national clinical trial, called PROTECT-1, inpatients with modera......ticals will collaborate in ajoint discovery effort targeting the identification of smallmolecules as potential antipsychotic medications. Any compoundsdiscovered as part of the research collaboration will be jointlyco-owned and patented by Wyeth and Solvay Pharmaceuticals as wellas co-developed and co-commerci...FDA approves MyocondaR IND for MAP in Crohn's Disease
...idate as an infectious causeof Crohn's Disease. By targeting the MAP infection, MyocondaR isdesigned to address a possible source of the disease, rather thanattempting to merely alleviate its symptoms. Except for historical information, this news release may containforward-looking statements that reflect the ......pronged phase2/3 clinical approach for Ceflatonin, targeting Gleevec-resistantCML patients who harbour the T315I mutation, as well as CMLpatients who have failed two tyrosine kinase inhibitors (usuallyGleevec and Sprycel). Gleevec(R)/Glivec(R) is a registered trademark of NovartisAG. Sprycel(R) is a register...Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide
...eptorand acts by a different mechanism than agents targeting theserotonergic system. The results of this study are being presentedtoday by Mayo Clinic investigator Viola Andresen, M.D. at theDigestive Disease Week conference in Washington, DC. Study Design and Results Thirty-six women suffering from IBS-C we......pronged phase 2/3 clinical approach forCeflatonin, targeting Gleevec-resistant CML patients who harbourthe T315I mutation, as well as CML patients who have failed twotyrosine kinase inhibitors (usually Gleevec and Sprycel). Gleevec®/Glivec® is a registered trademarkof Novartis AG. Sprycel® is a r...DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
...gement, with a number ofresearch programs underway targeting chronic disease and othertherapeutic areas. For more information, please visit <a target="_blank" href="http://www.durect.com/">www.durect.com . Forward-Looking Statement The statements in this press release regarding Memryte, itspotentia......s and death. Creating and deployingantiviral drugs targeting arenaviruses will enhance national andglobal security by acting as a significant deterrent and defenseagainst the use of arenaviruses as bioterror weapons. Six separatearenaviruses are classified as Category A pathogens by the Centersfor Disease Cont...Other ContentschickenpoxchickenpoxchillchillchillchildchildchildchildchildchildchildchildchildchildbirthchildbirthchillschillschlamydiachlamydiachlamydiachlamydiachiropracticchiropracticOther TagsPADPADcheermumssoreshindergumsOther Tagsqualities 2qualities 3plankton 2swimming 2swimming 3infertility 2
(Date:9/8/2008)...llan Nuclear Radiation Center (MNRC) in Sacramento... corrosion and defects in aircraft structure using...This technique is currently helping soil scientist... uptake of water and nutrients. , Scientists at ...lts from a newly developed non-invasive technique ...
(Date:9/8/2008)...y foods - bearded vultures do, too. A study by Ant...rotection Group in El Pont de Suert, Spain, has fo...rgy-dense bones and choose only the bones containi...n and delivery to its young. His findings will be ...ioral Ecology and Sociobiology . , The bearded v...
(Date:9/8/2008)...aded by Prof. Daniel Rosenfeld of the Institute of...lem, has come up with a surprising finding to the ...or decreases rainfall. The conclusion: both can be.... , The determination of this issue is one with...nge and specifically in areas suffering from manma...
(Date:9/8/2008)... "Smart water" may help boost production from oil...earchers in Norway report that injecting a special...n low-yield oil wells may help boost oil extractio...eet rising energy demands and provide consumers wi...ture, the scientists suggest. Their findings are s...
Breaking Biology News(10 mins):US Air Force technology helps scientists understand plant root function 2Scavenger birds chew the fat 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3American Chemical Society's Weekly PressPac -- Sept. 3, 2008 2American Chemical Society's Weekly PressPac -- Sept. 3, 2008 3American Chemical Society's Weekly PressPac -- Sept. 3, 2008 4American Chemical Society's Weekly PressPac -- Sept. 3, 2008 5American Chemical Society's Weekly PressPac -- Sept. 3, 2008 6American Chemical Society's Weekly PressPac -- Sept. 3, 2008 7American Chemical Society's Weekly PressPac -- Sept. 3, 2008 8GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 6081 1GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 6081 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 6081 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point of Care Test for Microalbuminuria a Kidney and Cardiovascular D 6076 1HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point of Care Test for Microalbuminuria a Kidney and Cardiovascular D 6076 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point of Care Test for Microalbuminuria a Kidney and Cardiovascular D 6076 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point of Care Test for Microalbuminuria a Kidney and Cardiovascular D 6076 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point of Care Test for Microalbuminuria a Kidney and Cardiovascular D 6076 5Best code for disease detection bar none 3677 1Invest in a future without dementia 22165 1Invest in a future without dementia 22165 2(Date:9/5/2008)... nonprofit organization,devoted to improving publi... launch of a new FDA Web site created to help the ...r (DTC) advertising of prescription,medications. T...sing," is,hosted by the FDA,s Center for Drug Eval...n partnership with EthicAd. For details, visit, ht...
(Date:9/5/2008)...ht or obese at age 45 , , FRIDAY, Sept. ...adults will develop osteoarthritis of the knee by ...in middle age, a new study says. , A person,s ...his or her body-mass index (BMI) rose, according t...study. People who were of normal weight at age 18 ...
(Date:9/5/2008)...ite shouldn,t overreact or stop taking them , ...S. Food and Drug Administration has started listin...ial safety issues, the agency said Friday. , "...we have begun analysis to determine whether there ...on," Dr. Gerald Dal Pan, director of the FDA,s Off...
(Date:9/5/2008)...are enhanced by taking into account risk factors b...ding to research teams led by epidemiologists at T...r in two complementary papers appearing in the Sep...In the first study to focus on African-Americans, ...d exposure to certain risks. Based upon these find...
Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |